- Home
- NKX vs PRME Comparison
NKX vs PRME Comparison
Compare NKX & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKX
- PRME
- Stock Information
- Founded
- NKX 2002
- PRME 2019
- Country
- NKX United States
- PRME United States
- Employees
- NKX N/A
- PRME N/A
- Industry
- NKX Finance/Investors Services
- PRME Medicinal Chemicals and Botanical Products
- Sector
- NKX Finance
- PRME Health Care
- Exchange
- NKX Nasdaq
- PRME Nasdaq
- Market Cap
- NKX 601.4M
- PRME 693.5M
- IPO Year
- NKX N/A
- PRME 2022
- Fundamental
- Price
- NKX $12.61
- PRME $5.95
- Analyst Decision
- NKX
- PRME Buy
- Analyst Count
- NKX 0
- PRME 6
- Target Price
- NKX N/A
- PRME $8.88
- AVG Volume (30 Days)
- NKX 109.3K
- PRME 3.9M
- Earning Date
- NKX 01-01-0001
- PRME 11-11-2025
- Dividend Yield
- NKX 4.37%
- PRME N/A
- EPS Growth
- NKX N/A
- PRME N/A
- EPS
- NKX N/A
- PRME N/A
- Revenue
- NKX N/A
- PRME $4,961,000.00
- Revenue This Year
- NKX N/A
- PRME $179.58
- Revenue Next Year
- NKX N/A
- PRME N/A
- P/E Ratio
- NKX N/A
- PRME N/A
- Revenue Growth
- NKX N/A
- PRME 739.42
- 52 Week Low
- NKX $9.78
- PRME $1.11
- 52 Week High
- NKX $12.00
- PRME $6.94
- Technical
- Relative Strength Index (RSI)
- NKX 57.91
- PRME 63.82
- Support Level
- NKX $12.60
- PRME $4.87
- Resistance Level
- NKX $12.61
- PRME $6.94
- Average True Range (ATR)
- NKX 0.11
- PRME 0.49
- MACD
- NKX -0.02
- PRME 0.08
- Stochastic Oscillator
- NKX 39.02
- PRME 55.90
About NKX Nuveen California AMT-Free Quality Municipal Income Fund
Nuveen California AMT-Free Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objectives are to provide current income exempt from regular federal and California income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.